Assessment of the differentiated aspiration process of palivizumab
OBJECTIVE: Assess the differentiated aspiration process of palivizumab, from planning to administration, and from the patient's profile to obtained savings as a result of the optimization of doses.METHODS: Cross-sectional study carried out by means of secondary data obtained from the medical records of 858 children. Variables of the study were as follows: information on the profile of cared children, amount of acquired and administered doses, vaccination procedure, and optimized doses. Data were extracted from care management reports.RESULTS: The innovative technique and the vaccination planning allowed for 98 children to be favored by leftovers of the medication, implying savings of R$ 1.144.347,52 in 2012 and 2013.CONCLUSION: The employment of the differentiated aspiration process favored the availability of the medication to 54 children other than those previously programmed, and the application of 78 leftovers. The establishment of a previous management planning process of programmed contents to be administered to children, in compliance with their profile, especially their body weight, favored the inclusion of other admitted newborns. The systematization process of the team work toward the administration of palivizumab implied the reduction of public expenditures.
Main Authors: | Albuquerque,Rosemeire Sartori de, Mariani Neto,Corintio, Arone,Gisleine Aparecida de Castro, Bersusa,Ana Aparecida Sanches, Leandro,Vanessa Peres |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Escola Paulista de Enfermagem, Universidade Federal de São Paulo
2014
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002014000100014 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Newborns' temperature submitted to radiant heat and to the Top Maternal device at birth
by: Albuquerque,Rosemeire Sartori de, et al.
Published: (2016) -
Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Manini,Mariana Bueno, et al.
Published: (2021) -
Perinatal Outcomes in Pregnant Women Users of Illegal Drugs
by: Oliveira,Tenilson Amaral, et al.
Published: (2016) -
Cost effectiveness of a protocol using palivizumab in preterm infants
by: Hernández-Gago,Yolanda, et al.
Published: (2017) -
Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
by: Salinas-Escudero,Guillermo, et al.
Published: (2012)